When people think of Indian technology, they likely think of outsourcing, programmers, and generic drugs everywhere. Few would imagine that the fastest Indian health hardware to break the $1 million mark on the U.S. crowdfunding market in 2026 is a neural stimulation patch made by a group of young people in Bangalore. This sleep device, DUSQ, launched on Kickstarter on June 9. Weighing 12 grams, it is worn behind the ear with an adhesive patch. While the user sleeps, it monitors the nervous system and delivers mild electrical stimulation to maintain longer periods of deep sleep. Early bird pricing starts at $229. After the 30‑day crowdfunding campaign, 4,326 backers paid a total of $1.23 million, setting a new record for Indian health tech companies on Kickstarter.
DUSQ addresses a problem most people don’t know about: after falling asleep, the sympathetic nervous system can surge 20 to 30 times a night. You never notice it, but each surge can pull you from deep sleep back into light sleep — one reason why some people still feel tired after a full eight hours. DUSQ monitors neural signals throughout the night, using an electrodermal activity (EDA) sensor to read nervous system signals. Its built‑in AI model identifies surge patterns and then delivers a brief, mild electrical current within seconds to stimulate the vagus and vestibular nerves behind the ear, intervening before the person is pulled out of deep sleep.
However, vagus‑nerve sleep aids in the form of headbands, neckbands, and wristbands have come and gone in waves. Modius, which received FDA clearance, was stuck in prescription channels and priced over a thousand dollars. The best‑selling Pulsetto remained just a small pre‑bedtime gadget. None became a hit. That’s why DUSQ’s crowdfunding success seems unusual: on a track where all predecessors failed, why has an undelivered device raised over a million dollars?
01 A ‘Sleep System’ Stuck Behind the Ear
Two years ago, DUSQ founder Siddhant Bhargava stood on the Shark Tank India stage and secured investment from three sharks with a stress‑relief patch. That product was the earliest predecessor of DUSQ. But a patch that gives only 10 minutes of relaxation has limited value; what they truly wanted was to help users relax over an extended period, especially during sleep. So the team completely overturned the product — redesigning the form factor, sensors, and software — and shifted the positioning from “a once‑a‑day tool” to “a system that runs through the night.” Since users always start using it in the evening before sleep, the product name DUSQ is a play on “dusk.”
The product itself is not complicated. It weighs 12 grams and is 7 mm thick, roughly the thickness of two stacked coins, and attaches behind the ear with a medical‑grade adhesive patch. Users need to replace the patch daily. Interestingly, the device is not worn only at bedtime; it requires users to wear it four hours before sleep. During those four hours, it collects neural signal data to assess your current nervous state. The logic: if you’re already highly tense before bed, your neural state after falling asleep is likely not great. Often, how well you sleep can be predicted before you even go to bed.
After the device makes an initial assessment of neural state, it delivers several stimuli at about 20% intensity before bedtime, causing a slight tingling sensation behind the ear to help the nervous system relax in advance. After falling asleep, the device switches to core working mode: the EDA sensor continuously reads signals, and the AI model identifies which neural fluctuation would pull the person out of deep sleep, then delivers a brief current at 2% to 4% intensity within seconds. According to the company, this intensity is below the skin perception threshold, so it does not affect the user’s sleep experience at night.
When you wake up, you receive a sleep report. It includes an interesting metric: SQ (Sleep Quotient). It doesn’t judge how well you slept last night, but rather your body’s current ability to generate sleep. This metric looks not only at nighttime data but also at the nervous system monitoring during the evening wearing period, incorporating the “four hours before sleep” state into evaluation. Because the hardware has an EDA sensor, it also reports the number and distribution of sympathetic surges each night and how many times the device intervened — the most direct reflection of its intervention capability. The charging case also has sensors to record ambient data. Light, noise, and temperature in the bedroom are correlated with sleep data for attribution analysis, for example, suggesting that poor deep sleep on a certain night may be related to high room temperature.
02 Electrifying Your Way to Sleep: Does It Really Work?
After understanding what DUSQ is, a more fundamental question emerges: theoretically, does electrifying your head to aid sleep actually work? Interestingly, the history of this technology is longer than most people think. Treating disease by electrically stimulating the vagus nerve has been around for almost 30 years. In 1997, the FDA approved an implantable device for severe epilepsy patients: surgery to wrap electrodes around the nerve, with lifelong follow‑up. Its real connection to sleep and ordinary people has only happened in the last three years. In 2023, the non‑invasive device from UK‑based Neurovalens received FDA clearance, with “treatment of insomnia” appearing as an indication for the first time. In 2024, a randomized controlled trial published in a JAMA subjournal showed that transcutaneous vagus nerve stimulation does improve chronic insomnia, and the effect lasted three months after treatment ended. So scientifically, there is a basis.
But why hasn’t anyone succeeded before? In fact, there have been many consumer attempts: vibrating Apollo Neuro, EEG‑reading Somnee, and FDA‑cleared Modius — none gained significant traction. The only one that broke out was Lithuanian company Pulsetto, a neck‑worn vagus nerve stimulator, which self‑reported revenue of over $40 million and 300,000 users in 2025. However, $40 million in revenue proves real paid demand for peripheral nerve stimulation, but it’s still an order of magnitude away from mainstream consumer products. Notably, Pulsetto’s path is daytime stress reduction, used only a few minutes a day, and it hasn’t entered the sleep scenario. DUSQ’s $1.23 million crowdfunding is the market’s first price tag for vagus‑nerve hardware entering the sleep space.
The DUSQ founding team believes it’s not the technology that fails, but the product form. Previous neuromodulation devices were all designed as “courses”: bulky, requiring active use by the user, and impossible to wear overnight. But sleep is an eight‑hour problem; if a device can’t accompany you through the whole night, it can never truly solve the problem. They did not take the more mainstream EEG route in brain‑computer interfaces but chose EDA, passing a very weak electrical current through the skin and sensing bodily responses through changes in skin conductance. DUSQ also made the device small enough that users barely feel it while sleeping, continuously monitoring heart rate, respiratory rate, neural signals, and other changes, feeding those data into a model for analysis, and then, based on the model’s predictions, deciding in real time when to stimulate and how strong.
The position behind the ear is chosen cleverly. One branch of the vagus nerve happens to reach the superficial skin here, the only vagal branch in the body that can be accessed without surgery. Next to it is the vestibular system of the inner ear, the same area that makes you drowsy on a train. This patch of skin is also one of the cleanest locations for collecting EDA signals. One coordinate, two sleep‑promoting nerves, plus a sensing window — combining these factors, they used anatomical methods to find this suitable contact point on the human body.
However, before being persuaded by this narrative, some caveats are worth noting. Most clinically validated uses of vagus nerve stimulation for sleep and stress involve fixed 30‑minute daily stimulation, with current adjusted to cause obvious tingling behind the ear, continuously for four to eight weeks — like a drug with dosage and course. DUSQ’s usage is overnight wear with on‑demand triggering, at only 2% to 4% of maximum intensity, so weak that you feel nothing all night, effectively diluting the proven dose by dozens of times. The modified effect has no precedent in the literature; currently only the company’s own data supports it, reporting 31% increase in deep sleep, 38% increase in heart rate variability, and 22% reduction in awakenings. Whether it really works won’t be known until the first users sleep with it; the product ships in October.
Beyond dosage, our research also found that in the key trial underlying the FDA clearance for vestibular stimulation, people wearing the real device had their insomnia index drop by 4.85 points over four weeks, while the sham‑device control group dropped by 3.14 points. In other words, much of the perceived improvement came from “wearing something electrified on the head” itself. Moreover, the device has many usage restrictions: people with skin allergies should not use it; those with pacemakers, cochlear implants, or metal implants in the head or neck are prohibited; and people with sleep apnea cannot use it as a substitute for a CPAP machine. It targets “sub‑health fatigue” and cannot replace professional medical devices.
03 A Doctor Who Twice Beat Severe Illness, Paired with a Sales‑Savvy Team
Behind DUSQ stands a person with an unusual resume. CEO Siddhant Bhargava is a doctor, but what drove him to entrepreneurship was not practicing medicine but being sick. He had lupus as a teenager and cancer in his twenties; he survived both. What’s interesting is his choices after recovery. After lupus, he founded a nutrition company Food Darzee, reportedly serving over 100,000 customers. After cancer, he pivoted to medical hardware, working on non‑invasive glucose monitoring, electronic socks for diabetic foot ulcers, and electronic diapers for stress urinary incontinence — all revolving around the body’s ability to repair itself. He summarizes that each experience ultimately led him back to the same problem: sleep. The body’s self‑repair mainly happens at night; if nighttime repair fails, any daytime product is just a patch. Realizing that gave birth to DUSQ.
The company’s team structure follows this logic. The technical foundation is led by Mitansh Khurana, a gold medalist in mathematics and computer science from BITS Pilani, India, responsible for firmware, real‑time signal processing, and the closed‑loop architecture. Hardware and manufacturing are handled by Shalmali Kadu, with the company’s own production line in India. Research design and safety frameworks are reviewed by external neurologists and psychiatrists. But it also emphasizes commercial capabilities. Co‑founder Gursakhi Lugani is a serial entrepreneur who has sold brands in 11 countries; growth advisor Ronak Shah has built DTC brands with over $100 million in sales. This track was previously dominated by scientist‑founders whose products worked but couldn’t sell. As it stands, DUSQ has assembled a team that values both clinical expertise and sales capability — from securing three Shark investors on Shark Tank India, to building a waitlist of 10,000, to reaching $1 million in crowdfunding in the first week — every step follows the playbook of a consumer brand.
In other words, the company’s ability to raise over a million dollars in crowdfunding is not only because the product is positioned in a growing market, but also because the team’s track record gives backers confidence in their delivery capability. When Bhargava talks about the product, one line is often repeated: “You don’t need to manage it; you just wake up different.” He wants to create a product that requires nothing from the user: stick it on, sleep, wake up. As to whether you really wake up different, this Indian doctor who twice got up from a sickbed has staked the answer on the first Americans who sleep with it after October.
